Development of new platform technology on Human and Animal vaccines
- Virus like particle vaccine
Virus-like particles (VLP) mimic the overall structure of virus particles but do not contain the infectious genetic material. When used as a vaccine, VLPs cause a robust immunogenic response due to their high-density display of epitopes and the capacity to present multiple proteins to the immune system. - Conjugated-Polysacharide vaccines
Conjugated vaccines are necessary for the protection of infants and young children because their immune systems are immature and do not respond to polysaccharide vaccines. The success of approved vaccines has already been proven; countless lives have been saved. A step-by-step approach to upstream and downstream processing of polysaccharide conjugated vaccines can be beneficial. - Viral vector vaccine
Viral vectors are vehicles that deliver the genetic payload to target cells. Advancements have been made in the vector design to ensure safety of these types of vaccines. This section describes a template to manufacture of adenovirus-based vaccine used in the bioprocessing industry. Compared to the conventional vaccines, adenovirus vector-based vaccines can express a wide range of antigens from virus, bacteria, or protozoan. They elicit long-term immune responses against infectious diseases
